![Margaret M. van Gilse](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Margaret M. van Gilse
Corporate Officer/Principal presso Bexion Pharmaceuticals, Inc.
Posizioni attive di Margaret M. van Gilse
Società | Posizione | Inizio | Fine |
---|---|---|---|
Bexion Pharmaceuticals, Inc.
![]() Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | Corporate Officer/Principal | - | - |
Storia della carriera di Margaret M. van Gilse
Statistiche
Distribuzione geografica
Stati Uniti | 2 |
Posizioni
Corporate Officer/Principal | 1 |
Settori
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Bexion Pharmaceuticals, Inc.
![]() Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | Commercial Services |